DVA
DaVita Inc.
DVA's fundamentals are mixed: earnings per share grew 39%, while its operating margin held steady at 15%. At 13x earnings, it's trading below its usual 15x. Analysts expect strong earnings growth.
DVA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Under pressure |
DVA's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is under pressure.
DVA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 11x | $174 | — |
| Cheap | 12x | $166 | -4.7% |
| Current | 13x | $174 | — |
| Fair | 15x | $202 | +16% |
| Expensive | 18x | $243 | +40% |
Historical ranges are pointers, not guarantees.
DVA's PE is in its cheap range at 13x. If earnings grow as analysts expect, today's price would be 11x next year's earnings.
DVA Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect DVA's earnings to grow and its profitability to improve, with its revenue holding steady.
DVA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $16.10 | +19% |
| Q3 2026 | $13.51 | +39% |
| Q2 2026 | $12.15 | +20% |
| Q1 2026 | $10.71 | +6.3% |
| Q4 2025 | $9.84 | -8.3% |
| Q3 2025 | $9.70 | +4.4% |
| Q2 2025 | $10.16 | +8% |
| Q1 2025 | $10.08 | +14% |
| Q4 2024 | $10.73 | +45% |
DVA earned $13.51 per share over the past year, up 39% from the year before.
DVA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.6B | +4.6% |
| Q2 2026 | $3.6B | +5.2% |
| Q1 2026 | $3.4B | +6% |
| Q4 2025 | $3.6B | +9.9% |
| Q3 2025 | $3.4B | +4.8% |
| Q2 2025 | $3.4B | +6.1% |
| Q1 2025 | $3.2B | +5% |
| Q4 2024 | $3.3B | +4.7% |
DVA's revenue has grown year over year for 15 quarters in a row: $3.6B last quarter, up 4.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | -0.8 points |
| Q2 2026 | 16% | +0.4 points |
| Q1 2026 | 14% | +0.5 points |
| Q4 2025 | 16% | -1.7 points |
| Q3 2025 | 15% | -1.6 points |
| Q2 2025 | 16% | 0 points |
| Q1 2025 | 14% | -2.1 points |
| Q4 2024 | 17% | +4.8 points |
DVA's operating margin was 14% last quarter, down 0.8 points from the same quarter a year ago.
DVA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $359.3M | -47% |
| Q2 2026 | $320.3M | +58% |
| Q1 2026 | $218.8M | +495% |
| Q4 2025 | $395.3M | +4.9% |
| Q3 2025 | $675.4M | +0.6% |
| Q2 2025 | $203.1M | -70% |
| Q1 2025 | $36.8M | +$292.6M |
| Q4 2024 | $377M | +16% |
DVA generated $1.3B in free cash flow over the past year, about the same as the year before.
DVA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.9% | -588K shares |
| 1 year | -11% | -8.3M shares |
| 3 years | -30% | -28.5M shares |
| 5 years | -40% | -44.3M shares |
| Available history | -57% | -88.3M shares |
DVA has 66M diluted shares, down 11% from a year ago, with $725M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $73M |
| Q2 2026 | $181.5M |
| Q1 2026 | $196.4M |
| Q4 2025 | $274.5M |
| Q3 2025 | $240.1M |
| Q2 2025 | $283.7M |
| Q1 2025 | $510.2M |
| Q4 2024 | $365.4M |
DVA spent $725M buying back its own shares over the past year, down 48% from the year before.
DVA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.6x | Elevated |
| Q2 2026 | 3.6x | Elevated |
| Q1 2026 | 3.6x | Elevated |
| Q4 2025 | 3.5x | Elevated |
| Q3 2025 | 3.5x | Elevated |
| Q2 2025 | 3.4x | Elevated |
| Q1 2025 | 3.4x | Elevated |
| Q4 2024 | 3.1x | Elevated |
DVA's net debt is about 3.6 years of its operating earnings (EBITDA), up from 3.5 years a year ago.
DVA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.2 | Neutral |
| Stochastic | 19.8 | Oversold |
DVA's weekly RSI is 44 (neutral) and its Stochastic is 20 (oversold).
DVA PE vs Healthcare Sector
| Metric | DVA | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 26 | 29 | 3 pts below |
DVA is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x.
DVA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $182.5 | 4.6% below |
| 20 week MA | $195.4 | 11% below |
| 50 week MA | $169.8 | 2.5% above |
| 100 week MA | $155.7 | 12% above |
| 200 week MA | $136.0 | 28% above |
DVA has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 28% above its 200-week average.
DVA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $74.8 | $115.1 | +54% |
| 2021 | $115.1 | $111.4 | -3.2% |
| 2022 | $111.4 | $73.8 | -34% |
| 2023 | $73.8 | $104.8 | +42% |
| 2024 | $104.8 | $154.3 | +47% |
| 2025 | $154.3 | $114.0 | -26% |
| 2026 YTD | $114.0 | $174.1 | +53% |
DVA is up 53% so far in 2026, after finishing lower in three of the previous six years.